IL-31RA: A Potential Drug Target and Biomarker (G133396)

Target Name: IL31RA

NCBI ID: G133396

IL31RA

IL-31RA: A Potential Drug Target and Biomarker

IL31RA (MGC125346) is a protein that is expressed in various tissues throughout the body, including the lungs, heart, kidneys, and intestines. It is a member of the interleukin-31 (IL-31) family, which includes several different proteins that play important roles in inflammation and immune responses.

IL-31RA is involved in several different processes in the body, including the regulation of inflammation and immune responses, as well as the regulation of cell growth and differentiation. It is thought to play a key role in the development and progression of a number of diseases, including cancer, autoimmune disorders, and respiratory diseases.

One of the main functions of IL-31RA is its role in the regulation of inflammation. IL-31RA has been shown to play a key role in the regulation of tissue inflammation, by helping to control the recruitment of immune cells to the site of inflammation and by contributing to the production of pro-inflammatory cytokines.

In addition to its role in inflammation, IL-31RA is also involved in the regulation of cell growth and differentiation. It has been shown to play a key role in the regulation of stem cell proliferation and the development of cancer, by contributing to the production of stem cells and by helping to control the production of pro-tumor cell types.

The potential clinical applications of IL-31RA as a drug target or biomarker are significant. If successful in these applications, IL-31RA could be used to treat a variety of conditions, including cancer, autoimmune disorders, and respiratory diseases.

For example, IL-31RA has been shown to be an effective drug target for the treatment of cancer, by inhibiting its activity and slowing its growth. This could make it an attractive option for the treatment of a variety of cancers, including breast, lung, and ovarian cancers.

IL-31RA has also been shown to be an effective biomarker for the diagnosis and prognosis of cancer. By measuring the levels of IL-31RA in cancer cells and tissues, doctors can get a sense of the level of inflammation and cell growth that is occurring within the body, which can be useful for the diagnosis and prognosis of cancer.

In addition to its potential clinical applications, IL-31RA is also an attractive candidate for further research into its biology and its potential mechanisms of action. By studying the role of IL-31RA in different organisms and in different contexts, researchers can gain a better understanding of its biology and its potential as a drug or biomarker.

Overall, IL-31RA is a protein that has significant potential as a drug target or biomarker, due to its involvement in the regulation of inflammation and cell growth, as well as its potential clinical applications in the treatment of cancer and other diseases. Further research is needed to fully understand its biology and its potential as a therapeutic agent.

Protein Name: Interleukin 31 Receptor A

Functions: Associates with OSMR to form the interleukin-31 receptor which activates STAT3 and to a lower extent STAT1 and STAT5 (PubMed:11877449, PubMed:14504285, PubMed:15627637, PubMed:15194700). May function in skin immunity (PubMed:15184896). Mediates IL31-induced itch, probably in a manner dependent on cation channels TRPA1 and TRPV1 (By similarity). Positively regulates numbers and cycling status of immature subsets of myeloid progenitor cells in bone marrow in vivo and enhances myeloid progenitor cell survival in vitro (By similarity)

The "IL31RA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL31RA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets